On Monday, Lexeo Therapeutics Inc (NASDAQ: LXEO) was 8.08% up from the session before settling in for the closing price of $1.98. A 52-week range for LXEO has been $1.45 – $19.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 14.77%. When this article was written, the company’s average yearly earnings per share was at 0.59%. With a float of $25.01 million, this company’s outstanding shares have now reached $33.07 million.
Let’s determine the extent of company efficiency that accounts for 72 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Lexeo Therapeutics Inc (LXEO) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lexeo Therapeutics Inc stocks. The insider ownership of Lexeo Therapeutics Inc is 24.67%, while institutional ownership is 83.16%. The most recent insider transaction that took place on Feb 19 ’25, was worth 19,091. In this transaction Chief Executive Officer of this company sold 4,326 shares at a rate of $4.41, taking the stock ownership to the 220,119 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Development Officer sold 1,486 for $4.41, making the entire transaction worth $6,558. This insider now owns 53,889 shares in total.
Lexeo Therapeutics Inc (LXEO) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.60% during the next five years compared to -99.98% drop over the previous five years of trading.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Trading Performance Indicators
You can see what Lexeo Therapeutics Inc (LXEO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.09, a number that is poised to hit -0.78 in the next quarter and is forecasted to reach -2.96 in one year’s time.
Technical Analysis of Lexeo Therapeutics Inc (LXEO)
Looking closely at Lexeo Therapeutics Inc (NASDAQ: LXEO), its last 5-days average volume was 1.4 million, which is a jump from its year-to-date volume of 0.65 million. As of the previous 9 days, the stock’s Stochastic %D was 30.95%. Additionally, its Average True Range was 0.49.
During the past 100 days, Lexeo Therapeutics Inc’s (LXEO) raw stochastic average was set at 9.47%, which indicates a significant decrease from 21.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 188.37% in the past 14 days, which was higher than the 136.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.4200, while its 200-day Moving Average is $7.9400. However, in the short run, Lexeo Therapeutics Inc’s stock first resistance to watch stands at $2.2400. Second resistance stands at $2.3400. The third major resistance level sits at $2.4700. If the price goes on to break the first support level at $2.0000, it is likely to go to the next support level at $1.8700. Should the price break the second support level, the third support level stands at $1.7700.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Key Stats
There are 33,197K outstanding shares of the company, which has a market capitalization of 71.05 million. As of now, sales total 0 K while income totals -98,330 K. Its latest quarter income was 0 K while its last quarter net income were -25,920 K.
